董事会薪酬与考核委员会工作细则 深圳迈瑞生物医疗电子股份有限公司 第一章 总则 第二章 人员组成 1 第一条 为建立健全深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）董 事及高级管理人员的考核和薪酬管理制度，完善公司治理结构，公司董 事会特决定下设董事会薪酬与考核委员会（以下简称"薪酬与考核委员 会"）。 第二条 为规范、高效地开展工作，公司董事会根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《上市公司独立董事管理办法》等有关法 律、法规和规范性文件以及《深圳迈瑞生物医疗电子股份有限公司章程》 （以下简称"《公司章程》"）的有关规定，制订本工作细则。 第三条 薪酬与考核委员会是董事会按照股东大会决议设立的专门工作机构，主 要负责制定公司董事及高级管理人员的考核标准并进行考核；负责制定、 审查公司董事及高级管理人员的薪酬政策与方案，对董事会负责。 第四条 薪酬与考核委员会所作决议，必须遵守《公司章程》、本工作细则及其 他有关法律、法规的规定。 第五条 薪酬与考核委员会成员由3至7名董事组成，其中独立董事应占多数。 第六条 薪酬与考核委员会设主任一名，由独立董事委员担任。 第七条 薪酬与考核委员 ...

深圳迈瑞生物医疗电子股份有限公司 独立董事工作制度 第一章 总则 独立董事应当按照相关法律、法规及《公司章程》的要求，认真履行职责， 维护公司整体利益，尤其要关注中小股东的合法权益不受损害。 独立董事应当独立履行职责，不受公司主要股东、实际控制人或者其他与 公司存在利害关系的单位或个人的影响。 第一条 为进一步完善深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"） 的治理结构，强化对内部董事及经理层的约束和激励机制，保护中小股东 及利益相关者的权益，促进公司的规范运作，根据《中华人民共和国公司 法》（以下简称"《公司法》"）《上市公司独立董事管理办法》等法律、 法规、规范性文件以及《深圳迈瑞生物医疗电子股份有限公司章程》（以下 简称"《公司章程》"）等有关规定，结合公司的实际情况，特制定本工 作制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及其主要股东、 实际控制人不存在直接或者间接利害关系，或者其他可能影响其进行独立 客观判断的关系的董事。 第三条 独立董事对公司及全体股东负有诚信和勤勉义务。 前款所指会计专业人士应当具备丰富的会计专业知识和经验，并至少符合 下列条件之一： （一） ...

深圳迈瑞生物医疗电子股份有限公司 2023 年度控股股东及其他关联方占用资金情况专项报告 关于深圳迈瑞生物医疗电子股份有限公司 控股股东及其他关联方占用资金情况专项报告 普华永道中天特审字(2024)第0807号 (第一页，共二页) 深圳迈瑞生物医疗电子股份有限公司董事会： 我们审计了深圳迈瑞生物医疗电子股份有限公司(以下简称"深圳迈瑞股 份")2023年12月31日的合并及公司资产负债表、2023年度合并及公司利润表、 合并及公司股东权益变动表、合并及公司现金流量表和财务报表附注(以下合称 "财务报表")，并于2024年4月25日出具了报告号为普华永道中天审字(2024) 第 10078 号的无保留意见审计报告。财务报表的编制和公允列报是深圳迈瑞股份 管理层的责任，我们的责任是在按照中国注册会计师审计准则执行审计工作的基 础上对财务报表整体发表审计意见。 在对上述财务报表执行审计的基础上，我们对后附的截至 2023 年 12 月 31 日止年度深圳迈瑞股份控股股东及其他关联方非经营性资金占用及其他关联资金 往来情况汇总表(以下简称"情况表")执行了有限保证的鉴证业务。 根据中国证券监督管理委员会《上市公司监 ...

深圳迈瑞生物医疗电子股份有限公司 2023 年度独立董事述职报告（吴祈耀） 本人（吴祈耀）作为深圳迈瑞生物医疗电子股份有限公司（下称"公司""上市公司"或"迈 瑞医疗"）的第七届董事会独立董事，在任职期间严格按照《中华人民共和国公司法》《中华 人民共和国证券法》及公司《独立董事工作制度》等相关法律法规、规范性文件和公司制度 的规定和要求，认真履行职责，充分发挥独立董事的独立性和专业性作用，维护公司整体利 益，维护全体股东尤其是中小股东的合法权益。现将 2023 年度担任独立董事的履职情况报告 如下： 一、基本情况 任期期间，本人投入足够的时间履行职责，努力做到亲自出席应出席的董事会及专门委 员会会议，参与董事会决策并对所议事项发表明确意见。未出现连续两次未能亲自出席，及 委托其他独立董事代为出席的情况。 1、出席董事会及股东大会的情况 2023 年度，迈瑞医疗董事会召开 5 次会议，召集召开股东大会 3 次。本人因任期届满于 2023 年 5 月 18 日离任，任职期间出席会议情况如下： | 董事姓名 | 应参加董 | 现场出席 董事会次 | 以通讯方式 参加董事会 | 委托出席 董事会次 | 缺席董事 | ...

深圳迈瑞生物医疗电子股份有限公司 2023 年度独立董事述职报告（姚辉） 本人（姚辉）作为深圳迈瑞生物医疗电子股份有限公司（下称"公司""上市公司"或"迈瑞 医疗"）的第七届董事会独立董事，在任职期间严格按照《中华人民共和国公司法》《中华人 民共和国证券法》及公司《独立董事工作制度》等相关法律法规、规范性文件和公司制度的 规定和要求，认真履行职责，充分发挥独立董事的独立性和专业性作用，维护公司整体利益， 维护全体股东尤其是中小股东的合法权益。现将 2023 年度担任独立董事的履职情况报告如 下： 一、基本情况 （一）工作履历、专业背景及兼职情况 本人姚辉，男，1964 年出生，中国国籍，无境外永久居留权。先后获得华东政法大学法 学学士学位，中国人民大学法学硕士、法学博士学位，曾于日本东京大学大学院法学政治学 研究科从事博士后研究。自 1991 年 7 月起历任中国人民大学法学院助教、讲师、副教授、教 授、博士生导师。2016 年 3 月至 2021 年 7 月任北京人大文化科技园建设发展有限公司董事。 2018 年 7 月至今任东北制药集团股份有限公司独立董事。2018 年 11 月至今任中国核工业建 设股份 ...

证券代码：300760 证券简称：迈瑞医疗 公告编号：2024-014 深圳迈瑞生物医疗电子股份有限公司 关于2023年度利润分配预案公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）于2024年4月25日召开第八届 董事会第六次和第八届监事会第五次会议，审议通过了《关于2023年度利润分配预案的议 案》，本议案尚需提交2023年年度股东大会审议。现将相关事项公告如下： 一、利润分配预案基本情况 根据普华永道中天会计师事务所（特殊普通合伙）出具的普华永道中天审字(2024)第 10078号审计报告，2023年度公司合并报表口径实现的归属于母公司所有者的净利润为 11,582,226,085.00元；根据《中华人民共和国公司法》（以下简称"《公司法》"）和《深圳 迈瑞生物医疗电子股份有限公司章程》（以下简称"《公司章程》"）的有关规定，当法定盈 余公积金累计额达到股本的50%以上时不再提取。截至2018年12月31日公司法定盈余公积 为607,845,633.00元，达到股本总额的50%，其后至2023年度 ...

Product Portfolio and Market Position - Mindray has achieved a broad product layout covering multiple clinical scenarios, including life information and support, in-vitro diagnostics, and medical imaging, with products used in emergency, inpatient, ICU, surgery, anesthesia, ultrasound, and laboratory settings[3] - The company has sold millions of medical devices globally, providing a solid foundation for its digital and intelligent transformation[4] - The company's products cover nearly 110,000 medical institutions in China, with a penetration rate of over 99% in top-tier hospitals[179] - In the international market, the company has achieved a top-three global market share in products such as patient monitors, anesthesia machines, ventilators, defibrillators, hematology analyzers, and ultrasound systems, with ultrasound systems reaching the top three globally for the first time[180] - The company's products and solutions have been adopted by 80 out of the top 100 hospitals globally as ranked by Newsweek[181] - The company's global ranking in the medical device industry has improved from 36th in 2020 to 27th in 2022, with 2023 revenue being 15% of the global leader[181] - The company has formed a comprehensive product portfolio covering life information and support, in vitro diagnostics, and medical imaging, spanning multiple medical fields and application scenarios[200] Digital and Intelligent Transformation - Mindray has established the "Three Rui" ecosystem, which includes "Rui Zhi Lian" for device interconnectivity, "Mindray Smart Lab" for laboratory management, and "Rui Ying Yun++" for imaging interconnectivity, enabling data flow and integration across devices[5] - The "Three Rui" ecosystem has significantly increased customer stickiness and serves as a cornerstone for Mindray's digital and intelligent transformation[6] - Mindray is transitioning from digital to intelligent medical devices, with products like patient monitors, diagnostic analyzers, and automated testing equipment integrating AI for real-time monitoring and improved diagnostic accuracy[4] - The company is building a comprehensive intelligent ecosystem that includes AI-assisted diagnostic tools, early warning systems, and critical care models, leveraging its extensive product portfolio and clinical understanding[8] - The company aims to develop a unique medical vertical domain model, utilizing accumulated data resources for continuous self-learning and evolution of AI models[9] - The company envisions a future where AI models analyze patient data before consultations, assist doctors in diagnosis, and ensure quality control throughout the healthcare workflow[9] - The company plans to initiate the digital intelligence era for China's medical device industry starting in 2024, positioning itself as a leader in this transformation[11] - The company emphasizes the importance of digital intelligence in breaking down barriers between departments, hospitals, and regions, enabling the redistribution and enhancement of medical resources and services[10] - The company has completed the initial construction of a "device + IT + AI" intelligent medical ecosystem, enhancing its global high-end customer penetration and brand loyalty[35] - The company's digital and intelligent solutions have been implemented in top-tier hospitals globally, including the US CHS Group, Belgium's Ghent University Hospital, and the UK's St Thomas' Hospital[60] - The company has developed the "Three Rui" IT smart medical solution ecosystem, enabling integration and innovation across medical devices and data consolidation[200] - The company has built a smart medical ecosystem integrating "devices + IT + AI," capable of providing customized hospital-wide digital solutions[200] - The company has achieved interoperability and integration across devices through fusion innovation and the "Three Rui" ecosystem[200] - The company utilizes AI to enable intelligent decision support, clinical automation, remote healthcare, and smart management, improving accuracy and efficiency[200] - The company has been exploring AI applications in medical devices since 2015, with several high-end products featuring AI-assisted diagnostic functions[200] Financial Performance - Revenue for 2023 reached RMB 34,931,900,884, a 15.04% increase compared to 2022[29] - Net profit attributable to shareholders in 2023 was RMB 11,582,226,085, up 20.56% year-over-year[29] - Basic earnings per share (EPS) for 2023 stood at RMB 9.5586, a 20.38% increase from 2022[30] - Total assets at the end of 2023 amounted to RMB 47,940,003,061, a 2.56% increase from the previous year[30] - Operating cash flow for 2023 was RMB 11,062,025,295, a decrease of 8.89% compared to 2022[30] - Q2 2023 revenue was the highest at RMB 10,111,491,655, followed by Q1 at RMB 8,364,281,841[31] - Net profit attributable to shareholders in Q2 2023 was RMB 3,870,873,576, the highest among all quarters[31] - Non-recurring gains and losses in 2023 totaled RMB 148,491,128, primarily driven by government subsidies and financial asset gains[32] - The company achieved operating revenue of 349,319.009 million yuan, a year-on-year increase of 15.04%, and net profit attributable to shareholders of 115,822.261 million yuan, a year-on-year increase of 20.56%[36] Subsidiaries and Shareholders - The company's subsidiaries include Mindray Animal Medical Technology Co., Ltd (MAHK) and Mindray Animal Medical Technology North America Co., Ltd. (MANA), both fully owned by Shenzhen Mindray Animal Medical Technology Co., Ltd[17] - Hytest Oy (HTOY) and Hytest LLC (HTRU) are subsidiaries of Hytest Invest Oy, which is also a subsidiary of the company[17] - DiaSys Diagnostic Systems GmbH (DiaSys/DSGM) and its subsidiaries form the DiaSys Group, a controlled subsidiary of the company[17] - The company holds shares in Shenzhen High-Performance Medical Devices Research Institute Co., Ltd and Shenzhen Hanuo Medical Technology Co., Ltd[17] - The company's major shareholders include Smartco Development Limited, Magnifice (HK) Limited, Ever Union (H.K.) Limited, Shenzhen Ruilong Consulting Services Partnership, and Shenzhen Ruifu Management Consulting Partnership[17] Research and Development - R&D investment reached 3.78 billion yuan, a year-on-year increase of 18.43%, accounting for 10.82% of revenue[81] - The company has 4,425 R&D engineers across 12 global R&D centers, with the Wuhan Research Institute project progressing smoothly[118] - Established a national high-performance medical device innovation center in collaboration with the Chinese Academy of Sciences and other institutions[120] - The company has developed a ventilation strategy evaluation function that integrates chest electrical impedance tomography (EIT) imaging, leveraging the "RuiZhiLian" ecosystem to assist in determining the success rate of weaning mechanical ventilation patients, addressing clinical pain points, particularly in primary hospitals[89] - The company has launched a comprehensive emergency solution that integrates modular transport ventilators and defibrillators, achieving physical and data fusion across pre-hospital, admission, and emergency transport scenarios, enhancing efficiency and data integrity[90] - In the field of in vitro diagnostics, the company has developed high-sensitivity cardiac markers (hs-TNI and NT-pro BNP) through the integration of its technology with HyTest's, improving sensitivity and precision for cardiovascular disease management[93] - The company has introduced a second-generation hypertension marker product, including aldosterone (ALD) and renin (Renin) assay kits, significantly improving sensitivity and specificity for primary aldosteronism screening[94] - The company has developed a B-cell cloning technology for direct monoclonal antibody production, eliminating the need for hybridoma cell fusion, resulting in higher cell viability and stability[95] - The company has launched the MT 8000 fully automated intelligent laboratory line, achieving a throughput of 3,600 tubes per hour and reducing sample processing time from 1 minute to 1 second[97] - The M980 fully automated biochemical and immunoassay line integrates biochemical and immunoassay modules, achieving one-machine-four-test efficiency and reducing biological safety risks[98] - BC-700 series fully automated blood cell analyzer achieves zero-cost detection of optical platelets in routine analysis mode through technological innovation, with over 40 patents applied[99] - The new blood sedimentation detection technology reduces blood usage to less than 10% of traditional Westergren method, enabling full automation of blood routine, CRP, SAA, and ESR parameter analysis[100] - EU 8600 series and EU-Pro series achieve a 14-class classification of urinary red cell subtypes, significantly reducing manual microscopy rates[101] - C·Lab Bridge expert interpretation system integrates sample status analysis, result analysis, processing suggestions, and case learning, enhancing coagulation testing efficiency[102] - Wireless probe technology in TE Air handheld ultrasound provides professional diagnostic-level image quality, meeting complex clinical needs[103] - POC ultrasound intelligent solution with AI recognition for cardiac structure and nerves, improving operational standardization and efficiency[104] - Micro-contrast imaging technology achieves micron-level resolution, enabling early diagnosis and differentiation of benign and malignant tumors[104] - DR automatic image quality control supports the promotion of "lower-level examination, upper-level diagnosis" in medical consortia[105] - Acquisition of HyTest Ltd. in 2021 enhances the company's self-sufficiency in IVD raw materials, with new myocardial and inflammation marker reagents launched in November 2023[109] - The company plans to increase R&D and operational investment in HyTest Ltd., aiming to achieve international top-tier competitiveness in chemiluminescence business within two years[109] - Completed the acquisition of 75% equity in DiaSys Diagnostic Systems GmbH for cash, making DiaSys a subsidiary of the company[110] - DiaSys has been integrated into the company's management system, with plans to enhance overseas IVD business through product empowerment and platform expansion[111] Market Expansion and International Presence - The company has established a global R&D, marketing, and service network with 12 R&D centers and 62 overseas subsidiaries in approximately 40 countries[37] - The company's international revenue in 2023 was approximately 13.5 billion RMB, with a market share in the low single digits[132] - The company's revenue in developing countries in 2023 was approximately 8.8 billion RMB, with a market share of less than 9%[132] - The company has broken into nearly 300 new high-end customers in the life information and support sector, over 450 in the in-vitro diagnostics sector, and over 200 in the medical imaging sector during the reporting period[180] - In Europe, the company successfully installed anesthesia machines and neonatal ICU equipment in key Spanish hospitals, and secured a major client in the Belgian Dutch-speaking region's top 5 non-university hospitals[71] - In developing markets, the company achieved a nearly $1 million installation in a Malaysian high-end public teaching hospital and secured a comprehensive solution for operating rooms and ICUs in a new Mexican hospital[72] - The company expanded its presence in the in-vitro diagnostics sector by breaking through over 450 new high-end customers, including 106 third-party chain laboratories[73] - In the UAE, the company became the exclusive blood cell supplier for a global chain laboratory in Saudi Arabia, Qatar, Bahrain, and Oman[75] - In the medical imaging sector, the company broke through over 200 new high-end customers, including globally ranked hospitals like Singapore General Hospital and Seoul National University Hospital[76] - The company successfully installed Resona R9T ultrasound devices in 6 hospitals in Hungary through a customized solution tailored to clinical needs[77] - In Norway, the company secured a full-hospital monitoring project at a top-three university hospital, further expanding its market share in Nordic high-end monitoring[71] - The company achieved a breakthrough in a Colombian private hospital by transitioning from single-product entry to a comprehensive operating room solution[72] - In Brazil, the company became the top blood cell market brand by securing demand projects across all 43 hospitals of a top-five private laboratory group[75] - Secured a $30 million monitoring equipment order in the US, the largest single order in the US market to date[79] - Covered over 80% of IDN healthcare systems in the US by the end of the reporting period[79] - Established global, regional, and national window hospitals to support international market expansion[78] Regulatory and Compliance - The company's products are certified under CE, FDA, ISO 13485, ISO 9001, ISO 14001, ISO 45001, and ISO 37001:2016 standards[18][19] - The company is recognized by CNAS and is a member of the China Association of Medical Equipment (CAME)[19] - The company collaborates with international testing and certification organizations such as Intertek, SGS, and TÜV[19] - The company has established a global registration lifecycle management platform covering over 100 countries[135] - The company continues to obtain EU CE certification and US FDA registration for new products, including MDR-compliant devices[136] - The company has established long-term partnerships with leading medical institutions in the US, UK, Italy, Spain, Germany, and France[136] - The company upgraded its "Business Conduct and Ethics Code" to enhance compliance and ethical standards[189] - MSCI upgraded the company's ESG rating to AA, recognizing achievements in environmental, social, and governance aspects[189] Industry Trends and Government Policies - The global medical device market size in 2023 was $595.2 billion, with a projected CAGR of 5.71% to reach $743.2 billion by 2027[140] - China's medical equipment market reached 1.27 trillion yuan in 2023, a year-on-year increase of 10.4%[142] - China's medical device industry revenue is expected to reach 1.875 trillion yuan by 2025, with a 10-year CAGR of 11.5%[143] - The overseas revenue ratio of Chinese medical device companies increased from 22% in 2018 to 34% in 2022, with the U.S. accounting for the highest proportion at 24.43% in 2023[145] - The issuance scale of medical special bonds in 2023 was approximately 265.674 billion yuan, accounting for nearly 10% of all special bonds, with the fourth quarter issuance at 8.018 billion yuan[148] - The total expenditure of China's basic medical insurance fund (including maternity insurance) in 2023 was 2,814.033 billion yuan, a year-on-year increase of 15.2%[149] - The government plans to arrange 3,900 billion yuan in local government special bonds in 2024, with an expected medical field budget of 390 billion yuan[148] - The number of medical visits in China in 2023 was 9.56 billion, a year-on-year increase of 13.54%[149] - The "Thousand Counties Project" aims to have at least 1,000 county hospitals reach the service level of tertiary hospitals by 2025[152] - The 2023 budget for medical service and security capacity improvement (medical institution capacity building) was approximately 6.274 billion yuan, with 3.046 billion yuan allocated to county-level medical institutions[152] - The government plans to promote equipment updates in seven major fields, including medical, with an estimated annual market size exceeding 5 trillion yuan[150] - The People's Bank of China established a 500 billion yuan re-loan for technological innovation and transformation to support equipment updates in key areas[150] - The government has increased support for county-level hospitals in national rural revitalization key assistance counties to 8 million yuan per county[152] - The demand for medical devices in county-level and below hospitals is expected to grow significantly, driven by increased healthcare investment and resource allocation[154] - The Chinese government plans to allocate 24,211 billion yuan for health expenditures in 2023, an increase of nearly 1,670 billion yuan compared to 2022[157] - By 2025, China aims to enhance its healthcare system, improve resource allocation, and strengthen disease prevention and emergency response capabilities[157] - The DRG/DIP payment reform is set to cover all eligible hospitals by 2025, promoting cost control and efficiency in healthcare delivery[159] - Centralized procurement of medical consumables will become the dominant model in public hospitals, aiming to reduce costs and improve access to healthcare[161] - The global medical device revenue of the top 10 companies in 2022 was approximately $220.3 billion, which is 15.21 times that of the top 10 Chinese medical device companies[164] - The global medical device revenue of the top 20 companies in 2022 was approximately $305.9 billion, which is 18.50 times that of the top 20 Chinese medical device companies[164] - The market share of the top 100 global medical device companies increased from 88.90% in 2019 to 94.08% in 2022, while the market share of the top 100 Chinese medical device companies increased from 20.90% in 2019 to 31.91% in 2022[165] - In 2023, the National Medical Products Administration approved 61 innovative medical devices, an increase of 6 compared to 2022[167] - The company had 6 models of electrocardiographs, 6 models of fully automated chemiluminescence immunoassay analyzers, and 4 models of small chemiluminescence immunoassay analyzers selected in the 9th batch of excellent domestic medical equipment products[166] - The National Medical Products Administration prioritized the approval of 12 medical devices in 2023[167] - The company's products were included in the 9th batch of excellent domestic medical equipment product directory, which was announced on June 16, 2023[166] - The National Health Commission and local governments have introduced policies to support the high-quality development of the medical device industry[165] - The National Medical Products Administration has accelerated the approval of innovative medical devices, with 61 approved in 2023, including products with international leading technologies[167] - The company's market concentration in China is still low, with significant room for improvement compared to global market data[165] - High-end medical equipment includes diagnostic, therapeutic, monitoring, and life support equipment, with a focus on innovative medical device development and application[169] - Beijing's DRG payment model excludes innovative medical devices and treatments from DRG payment, encouraging clinical value-driven innovation[169] - Shenzhen supports high-end medical device clusters, focusing on medical imaging, in vitro diagnostics, and AI applications in medical equipment[169] - The "Quality Power Construction Outline" emphasizes accelerating the upgrade of medical products and speeding up the review of urgently needed drugs and medical devices[169] - The "Medical Equipment Industry High-Quality Development Action Plan (2023-2025)" promotes the iterative upgrade of domestic medical equipment and supports talent development[170] - The "Industrial Structure Adjustment Guidance Catalog (2024)" encourages the development of high-end medical devices, including AI-assisted medical equipment and surgical robots[170] - AI and big data technologies are driving the digital transformation of the medical device industry, improving diagnostic accuracy and operational efficiency[171] - The

深圳迈瑞生物医疗电子股份有限公司 2023 年度独立董事述职报告（奚浩） 本人（奚浩）作为深圳迈瑞生物医疗电子股份有限公司（下称"公司""上市公司"或"迈 瑞医疗"）的第七届董事会独立董事，在任职期间严格按照《中华人民共和国公司法》《中华 人民共和国证券法》及公司《独立董事工作制度》等相关法律法规、规范性文件和公司制度 的规定和要求，认真履行职责，充分发挥独立董事的独立性和专业性作用，维护公司整体利 益，维护全体股东尤其是中小股东的合法权益。现将 2023 年度担任独立董事的履职情况报 告如下： 一、基本情况 （一）工作履历、专业背景及兼职情况 2023 年度，迈瑞医疗董事会召开 5 次会议，召集召开股东大会 3 次。本人因任期届满 于 2023 年 5 月 18 日离任，任职期间出席会议情况如下： 本人奚浩，男，1959 年出生，美国国籍。先后获得夏威夷大学（University of Hawaii） 学士学位和华盛顿大学（University of Washington）工商管理硕士学位。2004 年至 2008 年 任 JDSU 集团亚太区首席财务官。2006 年至 2016 年 3 月任迈瑞国际独立董 ...

第六条 提名委员会委员任期与同届董事会董事的任期相同。提名委员会因委员辞 职或免职或其他原因而导致人数低于本工作细则规定最低人数的三分之 二时，公司董事会应尽快选举产生新的委员。 在提名委员会委员人数达到本工作细则规定最低人数的三分之二以前，提 名委员会暂停行使本工作细则规定的职权。 第七条 《公司法》《公司章程》关于董事义务的规定适用于提名委员会委员。 深圳迈瑞生物医疗电子股份有限公司 董事会提名委员会工作细则 第一章 总则 第二章 人员组成 提名委员会主任负责召集和主持提名委员会会议，当提名委员会主任不能 或无法履行职责时，由其指定一名其他委员代行其职责。 1 第一条 为完善深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）法人治理 结构，增强董事会选举程序的科学性、民主性，优化董事会的组成人员结 构，公司特决定设立提名委员会（以下简称"提名委员会"）。 第二条 为使提名委员会规范、高效地开展工作，公司董事会根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《上市公司独立董事管理办法》 等有关法律、法规和规范性文件及《深圳迈瑞生物医疗电子股份有限公司 章程》（以下简称"《公司章程》"）的有关规定 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 证券代码：300760 证券简称：迈瑞医疗 公告编号：2024-016 深圳迈瑞生物医疗电子股份有限公司 关于修订公司章程的公告 | 提交董事会审议通过并披露: | | | | | | | | 提交董事会审议通过并披露: | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | …… | | | | | | | | …… | | | | | | 已按照本条第一款的规定履行相关义务的，不再 | | | | | | | | 已按照本条第一款的规定履行相关义务的，不再纳 | | | | | | | | 纳入相关的累计计算范围。 | | | 入相关的累计计算范围。 | | | | | | | | | | | | | | 公司拟进行应当披露的关联交易，应当在提交董 | | | | | | | | | | | | | | | | 事会审议之前，经全体独立董事过半数同意。 | | | 第一百二十五条 代表 1/10 以上表决权的股东、 | | | | ...